MCID: ANG054
MIFTS: 62

Angina Pectoris

Categories: Blood diseases, Cardiovascular diseases, Oral diseases, Rare diseases

Aliases & Classifications for Angina Pectoris

MalaCards integrated aliases for Angina Pectoris:

Name: Angina Pectoris 41 38 37
Prinzmetal's Variant Angina 12 76 53 73
Prinzmetal Angina 12 53 15
Variant Angina 12 53 55
Coronary Artery Vasospasm 53 73
Angina Pectoris, Variant 44 73
Angina Inversa 12 53
Angina 43 63
Variant Angina Pectoris 12
Prinzmetal's Angina 12
Vasospastic Angina 53

Classifications:



External Ids:

Disease Ontology 12 DOID:0111151
MeSH 44 D000788
KEGG 37 H01632
ICD10 33 I20 I20.1 I20.9

Summaries for Angina Pectoris

NIH Rare Diseases : 53 Prinzmetal's variant angina (PVA) is characterized by recurrent episodes of chest pain (angina) that usually occur when a person is at rest, between midnight and early morning. "Typical" angina, by contrast, is often triggered by physical exertion or emotional stress. Episodes of PVA can be very painful, and may last from several minutes to thirty minutes. In some cases the pain may spread from the chest to the head, shoulder, or arm. The pain associated with PVA is caused by a spasm in the arteries that supply blood to the heart muscle (coronary arteries). This results in an obstruction of blood flow. In some people, persistent spasms increase the risk for serious complications such as a life-threatening arrhythmia or heart attack. PVA most commonly occurs in people who smoke and people who have high cholesterol or high blood pressure. In many cases it occurs for unknown reasons in otherwise healthy people. In some cases it may be triggered by alcohol withdrawal, stress, exposure to cold, certain medications, or use of stimulants such as cocaine. The diagnosis of PVA involves findings on an electrocardiogram, evidence of the spasms on angiogram, and relief of sudden symptoms with medicines called nitrates. Treatment during an episode to relieve pain and shorten its duration involves sublingual nitroglycerin (a nitrate). Treatment to reduce the frequency of episodes and possibly reduce the risk of serious complications involves calcium channel blockers or long-acting nitrates. For people with PVA who smoke, quitting smoking can lead to a significant decrease in the frequency of episodes. While most people with PVA do not experience serious complications, it is a chronic condition that needs to be monitored over time.

MalaCards based summary : Angina Pectoris, also known as prinzmetal's variant angina, is related to atherosclerosis susceptibility and ischemia, and has symptoms including other and unspecified angina pectoris An important gene associated with Angina Pectoris is EDN1 (Endothelin 1), and among its related pathways/superpathways are Fluid shear stress and atherosclerosis and Platelet activation. The drugs Covera-HS and Nitroglycerin have been mentioned in the context of this disorder. Affiliated tissues include heart, spinal cord and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A coronary artery vasospasm characterized by spasms of the coronary arteries that occur while at rest, generally late at night or early in the morning, resulting in severe chest pain with preserved exercise capacity.

MedlinePlus : 43 Angina is chest pain or discomfort you feel when there is not enough blood flow to your heart muscle. Your heart muscle needs the oxygen that the blood carries. Angina may feel like pressure or a squeezing pain in your chest. It may feel like indigestion. You may also feel pain in your shoulders, arms, neck, jaw, or back. Angina is a symptom of coronary artery disease (CAD), the most common heart disease. CAD happens when a sticky substance called plaque builds up in the arteries that supply blood to the heart, reducing blood flow. There are three types of angina: Stable angina is the most common type. It happens when the heart is working harder than usual. Stable angina has a regular pattern. Rest and medicines usually help. Unstable angina is the most dangerous. It does not follow a pattern and can happen without physical exertion. It does not go away with rest or medicine. It is a sign that you could have a heart attack soon. Variant angina is rare. It happens when you are resting. Medicines can help. Not all chest pain or discomfort is angina. If you have chest pain, you should see your health care provider. NIH: National Heart, Lung, and Blood Institute

PubMed Health : 63 About angina: Angina (an-JI-nuh or AN-juh-nuh) is chest pain or discomfort that occurs if an area of your heart muscle doesn't get enough oxygen-rich blood.Angina may feel like pressure or squeezing in your chest. The pain also can occur in your shoulders, arms, neck, jaw, or back. Angina pain may even feel like indigestion.Angina isn't a disease; it's a symptom of an underlying heart problem. Angina usually is a symptom of coronary heart disease (CHD).CHD is the most common type of heart disease in adults. It occurs if a waxy substance called plaque (plak) builds up on the inner walls of your coronary arteries. These arteries carry oxygen-rich blood to your heart.

Wikipedia : 76 Variant angina, often termed Prinzmetal''s angina, Prinzmetal angina (/�?prɪnts-/), and less commonly... more...

Related Diseases for Angina Pectoris

Diseases related to Angina Pectoris via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 399)
# Related Disease Score Top Affiliating Genes
1 atherosclerosis susceptibility 32.1 CRP IL6 NOS3
2 ischemia 31.1 ACE EDN1 NOS3 PLAT
3 thrombosis 30.8 PLAT SERPINC1 VWF
4 intermediate coronary syndrome 30.7 ACE CRP IL6 PIK3C2A PLAT SERPINC1
5 coronary artery vasospasm 30.5 EDN1 NOS3 PIK3C2A
6 arteriosclerosis 30.5 ACE CRP EDN1 IL6
7 coronary thrombosis 30.4 PLAT SERPINC1 VWF
8 coronary artery anomaly 30.4 ACE CRP EDN1 NOS3 NPPB PIK3C2A
9 coronary stenosis 30.3 ACE CRP IL6 NPPB PIK3C2A VWF
10 acute myocardial infarction 30.3 ACE CRP EDN1 NPPB PIK3C2A PLAT
11 coronary restenosis 30.3 ACE SERPINC1
12 anterolateral myocardial infarction 30.3 ACE NPPB PLAT
13 arteries, anomalies of 30.2 ACE CRP EDN1 IL6 NOS3 NPPB
14 diabetes mellitus 30.2 ACE CRP EDN1 IL6 NOS3 PIK3C2A
15 dressler's syndrome 30.2 CRP PLAT
16 congestive heart failure 30.2 ACE EDN1 NPPB
17 ischemic heart disease 30.2 ACE CRP IL6 NOS3 NPPB
18 takayasu arteritis 30.1 CRP IL6 VWF
19 aortic valve disease 2 30.1 ACE CRP NPPB VWF
20 pericarditis 30.1 CRP IL6 NPPB
21 intermittent claudication 30.1 ACE CRP IL6 SERPINC1 VWF
22 kawasaki disease 30.1 CRP IL6 NPPB
23 thrombophilia due to thrombin defect 30.1 PLAT SERPINC1 VWF
24 antiphospholipid syndrome 30.1 PLAT SERPINC1 VWF
25 eisenmenger syndrome 30.0 EDN1 PLAT VWF
26 peripheral vascular disease 30.0 ACE CRP IL6 PLAT SERPINC1 VWF
27 left bundle branch hemiblock 30.0 ACE NPPB
28 aortic coarctation 30.0 ACE EDN1 NOS3
29 cardiac arrest 29.9 ACE NPPB PIK3C2A
30 myocardial stunning 29.9 EDN1 SERPINC1
31 intracranial embolism 29.9 PLAT SERPINC1
32 maturity-onset diabetes of the young, type 1 29.9 ACE CRP IL6
33 apnea, obstructive sleep 29.8 CRP EDN1 IL6
34 systolic heart failure 29.7 ACE CRP EDN1 IL6 NPPB
35 atrial fibrillation 29.7 ACE CRP NPPB PLAT VWF
36 thrombocytosis 29.7 CRP IL6 SERPINC1
37 hypercholesterolemia, familial 29.6 ACE APOA2 CRP NOS3
38 heart disease 29.6 ACE CRP EDN1 IL6 NOS3 NPPB
39 coronary heart disease 1 29.6 ACE APOA2 CRP EDN1 IL6 NOS3
40 connective tissue disease 29.5 ACE EDN1 IL6
41 stroke, ischemic 29.5 ACE CRP FGA NOS3 PLAT SERPINC1
42 purpura 29.5 CRP IL6 SERPINC1 VWF
43 inferior myocardial infarction 29.5 NPPB PIK3C2A PLAT
44 pulmonary hypertension, primary, 1 29.5 EDN1 FGA NPPB
45 myocardial infarction 29.5 ACE APOA2 CRP EDN1 FGA IL6
46 renovascular hypertension 29.5 ACE EDN1 NOS3
47 sleep apnea 29.4 ACE CRP EDN1 IL6 NOS3 NPPB
48 dilated cardiomyopathy 29.4 ACE CRP EDN1 IL6 NOS3 NPPB
49 cardiogenic shock 29.3 IL6 NPPB PIK3C2A PLAT
50 tetralogy of fallot 29.3 CRP EDN1 NPPB

Comorbidity relations with Angina Pectoris via Phenotypic Disease Network (PDN):


Chronic Myocardial Ischemia Esophagitis
Hypertension, Essential Intermediate Coronary Syndrome
Ischemic Heart Disease Mitral Valve Disease

Graphical network of the top 20 diseases related to Angina Pectoris:



Diseases related to Angina Pectoris

Symptoms & Phenotypes for Angina Pectoris

UMLS symptoms related to Angina Pectoris:


angina pectoris, other and unspecified angina pectoris

MGI Mouse Phenotypes related to Angina Pectoris:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.22 ACE CRP EDN1 FGA HTR1B IL6
2 homeostasis/metabolism MP:0005376 10.11 ACE APOA2 CRP EDN1 FGA IL6
3 hematopoietic system MP:0005397 10.01 ACE FGA IL6 NOS3 PIK3C2A PLAT
4 endocrine/exocrine gland MP:0005379 9.98 ACE EDN1 FGA HTR1B IL6 NOS3
5 immune system MP:0005387 9.97 ACE CRP FGA IL6 NOS3 PIK3C2A
6 mortality/aging MP:0010768 9.96 ACE EDN1 FGA HTR1B IL6 NOS3
7 digestive/alimentary MP:0005381 9.93 EDN1 FGA IL6 NOS3 PLAT VWF
8 adipose tissue MP:0005375 9.89 ACE HTR1B IL6 NOS3 PIK3C2A
9 nervous system MP:0003631 9.76 EDN1 FGA IL6 NOS3 PIK3C2A PLAT
10 renal/urinary system MP:0005367 9.43 ACE EDN1 IL6 NOS3 PIK3C2A SERPINC1
11 reproductive system MP:0005389 9.17 ACE FGA HTR1B IL6 NOS3 PLAT

Drugs & Therapeutics for Angina Pectoris

PubMedHealth treatment related to Angina Pectoris: 63

Treatments for angina include lifestyle changes, medicines, medical procedures, cardiac rehabilitation (rehab), and other therapies. The main goals of treatment are to:Reduce pain and discomfort and how often it occursPrevent or lower your risk for heart attack and death by treating your underlying heart conditionLifestyle changes and medicines may be the only treatments needed if your symptoms are mild and aren't getting worse. If lifestyle changes and medicines don't control angina, you may need medical procedures or cardiac rehab.Unstable angina is an emergency condition that requires treatment in a hospital.

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Covera-HS 18 VERAPAMIL HYDROCHLORIDE GD Searle, Alza January 1996

Drugs for Angina Pectoris (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 655)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitroglycerin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55-63-0 4510
2
Atenolol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 29122-68-7 2249
3
Nicorandil Approved, Investigational Phase 4,Phase 2,Not Applicable 65141-46-0 47528
4
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2 5949-44-0
5
Methyltestosterone Approved Phase 4,Phase 3,Phase 2 58-18-4 6010
6
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2 315-37-7 9416
7
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2 58-22-0 6013
8
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 50-78-2 2244
9
Pravastatin Approved Phase 4,Phase 3,Not Applicable 81093-37-0 54687
10
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 58-61-7 60961
11
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 274693-27-5 9871419
12
Amiodarone Approved, Investigational Phase 4,Not Applicable 1951-25-3 2157
13
Ranolazine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 142387-99-3, 95635-55-5 56959
14
Amlodipine Approved Phase 4,Phase 3,Phase 2,Not Applicable 88150-42-9 2162
15
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
16
Candesartan cilexetil Approved Phase 4,Phase 3,Phase 2,Not Applicable 145040-37-5 2540
17
Bisoprolol Approved Phase 4,Phase 2,Not Applicable 66722-44-9 2405
18
Diltiazem Approved, Investigational Phase 4,Not Applicable 42399-41-7 39186
19
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 113665-84-2, 120202-66-6 60606
20
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
21
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 772 46507594
22
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128270-60-0 16129704
23
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 72956-09-3 2585
24
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
25
Pantoprazole Approved Phase 4,Phase 3 102625-70-7 4679
26
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55142-85-3 5472
27
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
28
Rivaroxaban Approved Phase 4,Phase 3,Phase 2 366789-02-8
29
Chromium Approved Phase 4,Phase 2,Phase 3,Not Applicable 7440-47-3 27668
30
Cobalt Approved, Experimental Phase 4,Phase 2,Phase 3,Not Applicable 7440-48-4 104729
31 Nutmeg Approved Phase 4,Phase 3,Phase 2,Not Applicable
32
Simvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 79902-63-9 54454
33
Telmisartan Approved, Investigational Phase 4,Not Applicable 144701-48-4 65999
34
Amiloride Approved Phase 4,Phase 2,Phase 3,Not Applicable 2016-88-8, 2609-46-3 16231
35
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
36
Gliclazide Approved Phase 4,Early Phase 1 21187-98-4 3475
37
Glyburide Approved Phase 4,Phase 1 10238-21-8 3488
38
Metformin Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 657-24-9 14219 4091
39
Glimepiride Approved Phase 4,Phase 3 93479-97-1 3476
40
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
41
Valsartan Approved, Investigational Phase 4,Phase 3,Not Applicable 137862-53-4 60846
42
Citalopram Approved Phase 4,Phase 1,Phase 2 59729-33-8 2771
43
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177
44
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
45
Tenecteplase Approved Phase 4 191588-94-0
46
Tirofiban Approved Phase 4,Phase 3,Phase 2 144494-65-5 60947
47
Metoprolol Approved, Investigational Phase 4,Early Phase 1,Not Applicable 37350-58-6, 51384-51-1 4171
48
Chlorhexidine Approved, Vet_approved Phase 4,Not Applicable 55-56-1 2713 9552079
49
Colchicine Approved Phase 4,Phase 3,Phase 2 64-86-8 6167 2833
50
Etanercept Approved, Investigational Phase 4 185243-69-0

Interventional clinical trials:

(show top 50) (show all 1810)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Salvianolate Injection in Elderly Patients With Unstable Angina Pectoris Unknown status NCT03037047 Phase 4 0.9% Sodium Chloride Injection;salvianolate injection
2 Efficacy and Safety Study of Guanxin Shutong Capsule to Treat Chronic Stable Angina Unknown status NCT02280850 Phase 4 Guanxin Shutong Capsule;Placebo Capsule;nitroglycerine
3 Spinal Cord Stimulation (SCS) in Refractory Angina Unknown status NCT00121654 Phase 4
4 The Effect of Dan-shen Extract On Lipoprotein Associated PHospholipase A2 Levels IN Patients With Stable Angina Pectoris Unknown status NCT02870764 Phase 4 Dan-shen extract;Placebo
5 Efficacy Study of Atorvastatin to Treat Variant Angina Unknown status NCT00620204 Phase 4 atorvastatin
6 Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina. Unknown status NCT01397994 Phase 4 Nicorandil;Atenolol
7 Testosterone Therapy on Angina Threshold and Atheroma in Patients With Chronic Stable Angina Unknown status NCT00131183 Phase 4 Nebido
8 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
9 The Effects of Pravastatin and Rosuvastatin on Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
10 Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina Unknown status NCT02284048 Phase 4 ticagrelor
11 Safety of Amiodarone and Ranolazine Together in Patients With Angina Unknown status NCT01558830 Phase 4 ranolazine;placebo
12 A Pilot Study Exploring Efficacy and Safety of Amlodipine in the Stented Angina Patients Unknown status NCT01120327 Phase 4 Placebo;Amlodipine
13 Coronary Angioplasty in Octogenarians With Emergent Coronary Syndromes Unknown status NCT02126202 Phase 4
14 Treatment of Reperfusion Event by Vitamin C Infusion Unknown status NCT01090895 Phase 4 Vitamin C;Placebo
15 Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation Unknown status NCT01162902 Phase 4 Diltiazem treated group;Bisoprolol treated group;Candesartan treated group
16 Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI Unknown status NCT02012140 Phase 4 ticagrelor
17 Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image Unknown status NCT01769482 Phase 4 Udenafil;placebo
18 Small Coronary Artery Treated by TAXUS Liberté Registry in Japan Unknown status NCT00955214 Phase 4
19 Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome Unknown status NCT01372839 Phase 4 Atorvastatin;Statin
20 Ranolazine, Ethnicity and the Metabolic Syndrome Unknown status NCT01304095 Phase 4 Ranolazine
21 Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers Unknown status NCT02618837 Phase 4
22 Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
23 Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN) Unknown status NCT01735227 Phase 4 omeprazole;Pantoprazole
24 Efficacy Study of Nicorandil on Neointima Unknown status NCT02328521 Phase 4 Nicorandil;nicorandil placebo
25 Impact of Ticagrelor on the Endothelial Healing Following Drug-eluting Stent Implantation in the Patients With Acute Coronary Syndrome Unknown status NCT02037412 Phase 4 Ticagrelor;Clopidogrel
26 Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study. Unknown status NCT02251249 Phase 4 Paracetamol concentration time curve from 0 to 120 min
27 A Trial to Evaluate Efficacy of Heart-protecting Musk Pill Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
28 DEDICA (Dose of HEparin During Coronary Angioplasty) Trial Unknown status NCT01694459 Phase 4 Low-dose heparin;Standard dose heparin
29 Ranolazine Loading to Prevent PCI-induced Myocardial Injury Unknown status NCT01491061 Phase 4 Ranolazine;Placebo
30 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
31 Comparative Phase IV Study: Efficacy And Safety of TiTAN2 Versus COBALT-CHROME Stents- EVIDENCEII Unknown status NCT01918150 Phase 4
32 The Association Between Very Small Embryonic-like Stem Cells and the Prognosis of Coronary Artery Disease Patients Unknown status NCT01633359 Phase 4 Intensive statin;Routine statin
33 Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients Unknown status NCT01011660 Phase 4 Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
34 Italian Diffuse/Multivessel Disease ABSORB Prospective Registry: IT-Disappears Unknown status NCT02004730 Phase 4
35 Pravastatin for Acute Myocardial Infarction With Minimally to Mildly Increased Levels of Serum Cholesterol Study Unknown status NCT00688922 Phase 4 Pravastatin
36 Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial Unknown status NCT00700856 Phase 4 add-on pioglitazone;add-on sulphonylurea
37 Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor . Unknown status NCT02032303 Phase 4 Ticagrelor loading;Prasugrel loading
38 Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel Unknown status NCT02032290 Phase 4 ticagrelor loading;Clopidogrel loading
39 Ranolazine for Improving Symptoms of Palpitations Unknown status NCT01495520 Phase 4 Ranolazine;Placebo
40 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment Unknown status NCT01880879 Phase 4
41 Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome Unknown status NCT00815100 Phase 4 Ivabradine;Placebo
42 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
43 Testosterone for Peripheral Vascular Disease Unknown status NCT00504712 Phase 4 Testosterone;0.9% saline
44 The Canadian Prevention of Renal and Cardiovascular Endpoints Trial Unknown status NCT00231803 Phase 4
45 A Morbidity-Mortality and Remodeling Study With Valsartan Unknown status NCT00133328 Phase 4 valsartan
46 Effect of Ranolazine on Valvular Disease in Patients With Pacemakers Unknown status NCT01979965 Phase 4 Ranolazine (Active drug);Placebo
47 DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
48 Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism Unknown status NCT01084369 Phase 4 Testosterone
49 Vitamin D and Inflammatory Cytokine Levels After Acute Myocardial Infraction (MI) Unknown status NCT01115842 Phase 4 Vitamin D
50 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease Unknown status NCT01508663 Phase 4 ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.

Search NIH Clinical Center for Angina Pectoris

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: angina pectoris, variant

Genetic Tests for Angina Pectoris

Anatomical Context for Angina Pectoris

MalaCards organs/tissues related to Angina Pectoris:

41
Heart, Spinal Cord, Testes, Smooth Muscle, Lung, Endothelial, Neutrophil

Publications for Angina Pectoris

Articles related to Angina Pectoris:

(show top 50) (show all 1340)
# Title Authors Year
1
A multicenter trial of extracorporeal cardiac shock wave therapy for refractory angina pectoris: report of the highly advanced medical treatment in Japan. ( 29942978 )
2018
2
Revisiting angina pectoris with and without obstructive coronary artery disease. ( 29905817 )
2018
3
The clinical significance of echo-attenuated plaque in stable angina pectoris compared with acute coronary syndromes: A combined intravascular ultrasound and optical coherence tomography study. ( 29908828 )
2018
4
Economic Evaluation of Safflower Yellow Injection for the Treatment of Patients with Stable Angina Pectoris in China: A Cost-Effectiveness Analysis. ( 29431470 )
2018
5
High-Sensitivity Cardiac Troponin I and the Diagnosis of Coronary Artery Disease in Patients With Suspected Angina Pectoris. ( 29444926 )
2018
6
Cardiac Troponin T Concentrations, Reversible Myocardial Ischemia, and Indices of Left Ventricular Remodeling in Patients with Suspected Stable Angina Pectoris: a DOPPLER-CIP Substudy. ( 29959147 )
2018
7
Effect of Kuanxiong Aerosol () on Patients with Angina Pectoris: A Non-inferiority Multi-center Randomized Controlled Trial. ( 29435729 )
2018
8
Clinical Acceptability Of Trimetazidine Modified-Release 80A mg Once Daily Versus Trimetazidine Modified-Release 35A mg Twice Daily In Stable Angina Pectoris. ( 29779201 )
2018
9
Blood rheology of angina pectoris patients with myocardial injury after ischemia reperfusion and its effect on thromboxane B<sub>2</sub>levels. ( 29399084 )
2018
10
The Effectiveness of Trimetazidine Treatment in Patients with Stable Angina Pectoris of Various Durations: Results from the CHOICE-2 Study. ( 29766461 )
2018
11
In-flight angina pectoris; an unusual presentation. ( 29699500 )
2018
12
Psychotic experiences as an independent risk factor for angina pectoris in 48 low- and middle-income countries. ( 29856560 )
2018
13
The associatA+on between serum serglycin level and coronary artery disease severity in patients with stable angina pectoris. ( 29313562 )
2018
14
A randomized, triple-blind trial of cardiac shock-wave therapy on exercise tolerance and symptoms in patients with stable angina pectoris. ( 29912782 )
2018
15
Relationship Between Prodromal Angina Pectoris and Neutrophil-to Lymphocyte Ratio in Patients With ST Elevation Myocardial Infarction. ( 29735396 )
2018
16
Usefulness of stellate ganglion block for refractory angina pectoris. ( 29904316 )
2018
17
Sodium Tanshinone II A Sulfonate Injection as Adjuvant Treatment for Unstable Angina Pectoris: A Meta-Analysis of 17 Randomized Controlled Trials. ( 29181731 )
2018
18
National Prevalence of Self-Reported Coronary Heart Disease and Chronic Stable Angina Pectoris: Factor Analysis of the Underlying Cardiometabolic Risk Factors in the Fourth Round of the SuRFNCD-2011. ( 29434010 )
2018
19
Protein biomarkers and coronary microvascular dilatation assessed by rubidium-82 PET in women with angina pectoris and no obstructive coronary artery disease. ( 29981522 )
2018
20
Angina Pectoris in Young Male due to Agenesis of Left Circumflex Artery. ( 29717103 )
2018
21
The correlation between speckle tracking echocardiography and coronary artery disease in patients with suspected stable angina pectoris. ( 29961454 )
2018
22
Short term clinical outcomes of Everolimus-eluting stents in patients with stable angina pectoris. ( 29805386 )
2018
23
Plasma 25-hydroxyvitamin D and mortality in patients with suspected stable angina pectoris. ( 29325121 )
2018
24
Ginkgo Leaf Extract and Dipyridamole Injection as Adjuvant Treatment for Angina Pectoris: A Meta-Analysis of 41 Randomized Controlled Trials. ( 29752694 )
2018
25
CT-based total vessel plaque analyses improves prediction of hemodynamic significance lesions as assessed by fractional flow reserve in patients with stable angina pectoris. ( 29866619 )
2018
26
THE INCREASE OF EFFICIENCY OF TREATMENT IN PATIENTS WITH NON-STABLE ANGINA PECTORIS WITH USE OF NITROGEN OXIDE DONATOR WZROST SKUTECZNOA9CI LECZENIA CHORYCH Z NIESTABILNA8 DA8AWICA8 PIERSIOWA8 PRZY POMOCY DONORA9W TLENKU AZOTU. ( 29786574 )
2018
27
Ischemic Modified Albumin Predicts Critical Coronary Artery Disease in Unstable Angina Pectoris and Non-ST-Elevation Myocardial Infarction. ( 29904441 )
2018
28
Association of plasma pentraxin-3 levels with coronary risk factors and the lipid profile: a cross-sectional study in Japanese patients with stable angina pectoris. ( 29789902 )
2018
29
Accelerated collagen turnover in women with angina pectoris without obstructive coronary artery disease: An iPOWER substudy. ( 29436257 )
2018
30
Serum Carnitine Metabolites and Incident Type 2 Diabetes Mellitus in Patients with Suspected Stable Angina Pectoris. ( 29325058 )
2018
31
Adherence to the Healthy Nordic Food Index and the incidence of acute myocardial infarction and mortality among patients with stable angina pectoris. ( 30091209 )
2018
32
Usefulness of Higher Levels of Cardiac Troponin T in Patients With Stable Angina Pectoris to Predict Risk of Acute Myocardial Infarction. ( 30146101 )
2018
33
Doppler Versus Thermodilution-Derived Coronary Microvascular Resistance to Predict Coronary Microvascular Dysfunction in Patients With Acute Myocardial Infarction or Stable Angina Pectoris. ( 29132649 )
2018
34
Intramural Coronary Amyloidosis Mimicking Effort Angina Pectoris Preceding Fatal Heart Failure. ( 30197408 )
2018
35
Predictive value of depression and anxiety for long-term mortality: differences in outcome between acute coronary syndrome and stable angina pectoris. ( 28992998 )
2018
36
The Reducer device in patients with angina pectoris: mechanisms, indications, and perspectives. ( 29020417 )
2018
37
Effect of sex difference in clinical presentation (stable coronary artery disease vs unstable angina pectoris or non-ST-elevation myocardial infarction vs ST-elevation myocardial infarction) on 2-year outcomes in patients undergoing percutaneous coronary intervention. ( 29023996 )
2018
38
Corrigendum to: Chronic refractory angina pectoris: recent progress and remaining challenges. ( 29186406 )
2018
39
Nuclear myocardial perfusion imaging in stable angina pectoris : Sometimes being wrong is all right. ( 29524163 )
2018
40
Chinese herbal injections for unstable angina pectoris: A protocol for systematic review and network meta-analyses. ( 29561418 )
2018
41
Neopterin and Cardiovascular Events Following Coronary Stent Implantation in Patients with Stable Angina Pectoris. ( 29593175 )
2018
42
Acupuncture for stable angina pectoris: a systematic review protocol. ( 29622575 )
2018
43
Vascular Healing Response after Everolimus-Eluting Stent Implantation in Acute Coronary Syndrome Culprit Lesions: Comparison with Implantation in Stable Angina Pectoris. ( 29643697 )
2018
44
Relationship between C-reactive protein/albumin ratio and coronary artery disease severity in patients with stable angina pectoris. ( 29667724 )
2018
45
Ascending Aortic Strain Analysis Using 2-Dimensional Speckle Tracking Echocardiography Improves the Diagnostics for Coronary Artery Stenosis in Patients With Suspected Stable Angina Pectoris. ( 29982229 )
2018
46
Tools to improve the diagnostic accuracy of exercise electrocardiograms in patients with atypical angina pectoris. ( 30024394 )
2018
47
An unusual cause of angina pectoris due to dynamic coronary artery compression and successful treatment with cardiac surgical reconstruction. ( 30053112 )
2018
48
Impact of statins preloading before PCI on periprocedural myocardial infarction among stable angina pectoris patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. ( 30056022 )
2018
49
Usefulness of Postsystolic Shortening to Diagnose Coronary Artery Disease and Predict Future Cardiovascular Events in Stable Angina Pectoris. ( 30077186 )
2018
50
Nicorandil improves clinical outcomes in patients with stable angina pectoris requiring PCI: a systematic review and meta-analysis of 14 randomized trials. ( 30079778 )
2018

Variations for Angina Pectoris

Expression for Angina Pectoris

LifeMap Discovery
Genes differentially expressed in tissues of Angina Pectoris patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 EGR3 early growth response 3 Blood + 4.04 0.001
Search GEO for disease gene expression data for Angina Pectoris.

Pathways for Angina Pectoris

GO Terms for Angina Pectoris

Cellular components related to Angina Pectoris according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.95 ACE APOA2 FGA PIK3C2A PLAT SERPINC1
2 endoplasmic reticulum lumen GO:0005788 9.62 APOA2 FGA IL6 SERPINC1
3 blood microparticle GO:0072562 9.61 APOA2 FGA SERPINC1
4 extracellular space GO:0005615 9.61 ACE APOA2 CRP EDN1 FGA IL6
5 collagen-containing extracellular matrix GO:0062023 9.56 FGA PLAT SERPINC1 VWF
6 platelet alpha granule GO:0031091 9.37 FGA VWF
7 extracellular region GO:0005576 9.32 ACE APOA2 CRP EDN1 FGA IL6
8 Weibel-Palade body GO:0033093 9.16 EDN1 VWF

Biological processes related to Angina Pectoris according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.8 APOA2 FGA IL6 SERPINC1
2 platelet activation GO:0030168 9.69 FGA IL6 VWF
3 cellular protein metabolic process GO:0044267 9.62 APOA2 FGA IL6 SERPINC1
4 protein kinase C-activating G protein-coupled receptor signaling pathway GO:0007205 9.58 EDN1 HTR1B
5 regulation of vasoconstriction GO:0019229 9.58 ACE EDN1
6 fibrinolysis GO:0042730 9.57 FGA PLAT
7 vasoconstriction GO:0042310 9.56 EDN1 HTR1B
8 positive regulation of renal sodium excretion GO:0035815 9.55 EDN1 NPPB
9 positive regulation of urine volume GO:0035810 9.54 EDN1 NPPB
10 regulation of blood vessel diameter GO:0097746 9.52 ACE NPPB
11 plasminogen activation GO:0031639 9.48 FGA PLAT
12 body fluid secretion GO:0007589 9.46 EDN1 NPPB
13 blood coagulation GO:0007596 9.46 FGA PLAT SERPINC1 VWF
14 negative regulation of lipid storage GO:0010888 9.43 CRP IL6
15 hemostasis GO:0007599 9.43 FGA SERPINC1 VWF
16 neutrophil mediated immunity GO:0002446 9.4 ACE IL6
17 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.37 EDN1 NOS3
18 regulation of blood vessel size GO:0050880 9.13 EDN1 NOS3 NPPB
19 regulation of blood pressure GO:0008217 8.92 ACE EDN1 NOS3 NPPB

Molecular functions related to Angina Pectoris according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 8.92 EDN1 FGA NPPB PLAT

Sources for Angina Pectoris

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....